Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine

Cynthia G. Whitney, Monica M. Farley, James Hadler, Lee H. Harrison, Nancy M. Bennett, Ruth Lynfield, Arthur Reingold, Paul R. Cieslak, Tamara Pilishvili, Delois Jackson, Richard R. Facklam, James H. Jorgensen, Anne Schuchat

Research output: Contribution to journalArticle

1796 Citations (Scopus)

Abstract

BACKGROUND: In early 2000, a protein-polysaccharide conjugate vaccine targeting seven pneumococcal serotypes was licensed in the United States for use in young children. METHODS: We examined population-based data from the Active Bacterial Core Surveillance of the Centers for Disease Control and Prevention to evaluate changes in the burden of invasive disease, defined by isolation of streptococcus pneumoniae from a normally sterile site. Serotyping and susceptibility testing of isolates were performed. We assessed trends using data from seven geographic areas with continuous participation from 1998 through 2001 (population, 16 million). RESULTS: The rate of invasive disease dropped from an average of 24.3 cases per 100,000 persons in 1998 and 1999 to 17.3 per 100,000 in 2001. The largest decline was in children under two years of age. In this group, the rate of disease was 69 percent lower in 2001 than the base-line rate (59.0 cases per 100,000 vs. 188.0 per 100,000, P<0.001); the rate of disease caused by vaccine and vaccine-related serotypes declined by 78 percent (P<0.001) and 50 percent (P<0.001), respectively. Disease rates also fell for adults; as compared with baseline, the rate of disease in 2001 was 32 percent lower for adults 20 to 39 years of age (7.6 cases per 100,000 vs. 11.2 per 100,000, P<0.001), 8 percentlower for those 40 to 64 years of age (19.7 per 100,000 vs. 21.5 per 100,000, P=0.03), and 18 percent lower for those 65 years of age or more (49.5 per 100,000 vs. 60.1 per 100,000, P<0.001). The rate of disease caused by strains that were not susceptible to penicillin was 35 percent lower in 2001 than in 1999 (4.1 cases per 100,000 vs. 6.3 per 100,000, P<0.001). CONCLUSIONS: The use of the pneumococcal conjugate vaccine is preventing disease in young children, for whom the vaccine is indicated, and may be reducing the rate of disease in adults. The vaccine provides an effective new tool for reducing disease caused by drug-resistant strains.

Original languageEnglish (US)
Pages (from-to)1737-1746
Number of pages10
JournalNew England Journal of Medicine
Volume348
Issue number18
DOIs
StatePublished - May 1 2003

Fingerprint

Conjugate Vaccines
Polysaccharides
Proteins
Vaccines
Serotyping
Pneumococcal Vaccines
Centers for Disease Control and Prevention (U.S.)
Streptococcus pneumoniae
Penicillins
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Whitney, C. G., Farley, M. M., Hadler, J., Harrison, L. H., Bennett, N. M., Lynfield, R., ... Schuchat, A. (2003). Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. New England Journal of Medicine, 348(18), 1737-1746. https://doi.org/10.1056/NEJMoa022823

Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. / Whitney, Cynthia G.; Farley, Monica M.; Hadler, James; Harrison, Lee H.; Bennett, Nancy M.; Lynfield, Ruth; Reingold, Arthur; Cieslak, Paul R.; Pilishvili, Tamara; Jackson, Delois; Facklam, Richard R.; Jorgensen, James H.; Schuchat, Anne.

In: New England Journal of Medicine, Vol. 348, No. 18, 01.05.2003, p. 1737-1746.

Research output: Contribution to journalArticle

Whitney, CG, Farley, MM, Hadler, J, Harrison, LH, Bennett, NM, Lynfield, R, Reingold, A, Cieslak, PR, Pilishvili, T, Jackson, D, Facklam, RR, Jorgensen, JH & Schuchat, A 2003, 'Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine', New England Journal of Medicine, vol. 348, no. 18, pp. 1737-1746. https://doi.org/10.1056/NEJMoa022823
Whitney, Cynthia G. ; Farley, Monica M. ; Hadler, James ; Harrison, Lee H. ; Bennett, Nancy M. ; Lynfield, Ruth ; Reingold, Arthur ; Cieslak, Paul R. ; Pilishvili, Tamara ; Jackson, Delois ; Facklam, Richard R. ; Jorgensen, James H. ; Schuchat, Anne. / Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. In: New England Journal of Medicine. 2003 ; Vol. 348, No. 18. pp. 1737-1746.
@article{357da166ddb0459f87f8c5c23d1c136f,
title = "Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine",
abstract = "BACKGROUND: In early 2000, a protein-polysaccharide conjugate vaccine targeting seven pneumococcal serotypes was licensed in the United States for use in young children. METHODS: We examined population-based data from the Active Bacterial Core Surveillance of the Centers for Disease Control and Prevention to evaluate changes in the burden of invasive disease, defined by isolation of streptococcus pneumoniae from a normally sterile site. Serotyping and susceptibility testing of isolates were performed. We assessed trends using data from seven geographic areas with continuous participation from 1998 through 2001 (population, 16 million). RESULTS: The rate of invasive disease dropped from an average of 24.3 cases per 100,000 persons in 1998 and 1999 to 17.3 per 100,000 in 2001. The largest decline was in children under two years of age. In this group, the rate of disease was 69 percent lower in 2001 than the base-line rate (59.0 cases per 100,000 vs. 188.0 per 100,000, P<0.001); the rate of disease caused by vaccine and vaccine-related serotypes declined by 78 percent (P<0.001) and 50 percent (P<0.001), respectively. Disease rates also fell for adults; as compared with baseline, the rate of disease in 2001 was 32 percent lower for adults 20 to 39 years of age (7.6 cases per 100,000 vs. 11.2 per 100,000, P<0.001), 8 percentlower for those 40 to 64 years of age (19.7 per 100,000 vs. 21.5 per 100,000, P=0.03), and 18 percent lower for those 65 years of age or more (49.5 per 100,000 vs. 60.1 per 100,000, P<0.001). The rate of disease caused by strains that were not susceptible to penicillin was 35 percent lower in 2001 than in 1999 (4.1 cases per 100,000 vs. 6.3 per 100,000, P<0.001). CONCLUSIONS: The use of the pneumococcal conjugate vaccine is preventing disease in young children, for whom the vaccine is indicated, and may be reducing the rate of disease in adults. The vaccine provides an effective new tool for reducing disease caused by drug-resistant strains.",
author = "Whitney, {Cynthia G.} and Farley, {Monica M.} and James Hadler and Harrison, {Lee H.} and Bennett, {Nancy M.} and Ruth Lynfield and Arthur Reingold and Cieslak, {Paul R.} and Tamara Pilishvili and Delois Jackson and Facklam, {Richard R.} and Jorgensen, {James H.} and Anne Schuchat",
year = "2003",
month = "5",
day = "1",
doi = "10.1056/NEJMoa022823",
language = "English (US)",
volume = "348",
pages = "1737--1746",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "18",

}

TY - JOUR

T1 - Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine

AU - Whitney, Cynthia G.

AU - Farley, Monica M.

AU - Hadler, James

AU - Harrison, Lee H.

AU - Bennett, Nancy M.

AU - Lynfield, Ruth

AU - Reingold, Arthur

AU - Cieslak, Paul R.

AU - Pilishvili, Tamara

AU - Jackson, Delois

AU - Facklam, Richard R.

AU - Jorgensen, James H.

AU - Schuchat, Anne

PY - 2003/5/1

Y1 - 2003/5/1

N2 - BACKGROUND: In early 2000, a protein-polysaccharide conjugate vaccine targeting seven pneumococcal serotypes was licensed in the United States for use in young children. METHODS: We examined population-based data from the Active Bacterial Core Surveillance of the Centers for Disease Control and Prevention to evaluate changes in the burden of invasive disease, defined by isolation of streptococcus pneumoniae from a normally sterile site. Serotyping and susceptibility testing of isolates were performed. We assessed trends using data from seven geographic areas with continuous participation from 1998 through 2001 (population, 16 million). RESULTS: The rate of invasive disease dropped from an average of 24.3 cases per 100,000 persons in 1998 and 1999 to 17.3 per 100,000 in 2001. The largest decline was in children under two years of age. In this group, the rate of disease was 69 percent lower in 2001 than the base-line rate (59.0 cases per 100,000 vs. 188.0 per 100,000, P<0.001); the rate of disease caused by vaccine and vaccine-related serotypes declined by 78 percent (P<0.001) and 50 percent (P<0.001), respectively. Disease rates also fell for adults; as compared with baseline, the rate of disease in 2001 was 32 percent lower for adults 20 to 39 years of age (7.6 cases per 100,000 vs. 11.2 per 100,000, P<0.001), 8 percentlower for those 40 to 64 years of age (19.7 per 100,000 vs. 21.5 per 100,000, P=0.03), and 18 percent lower for those 65 years of age or more (49.5 per 100,000 vs. 60.1 per 100,000, P<0.001). The rate of disease caused by strains that were not susceptible to penicillin was 35 percent lower in 2001 than in 1999 (4.1 cases per 100,000 vs. 6.3 per 100,000, P<0.001). CONCLUSIONS: The use of the pneumococcal conjugate vaccine is preventing disease in young children, for whom the vaccine is indicated, and may be reducing the rate of disease in adults. The vaccine provides an effective new tool for reducing disease caused by drug-resistant strains.

AB - BACKGROUND: In early 2000, a protein-polysaccharide conjugate vaccine targeting seven pneumococcal serotypes was licensed in the United States for use in young children. METHODS: We examined population-based data from the Active Bacterial Core Surveillance of the Centers for Disease Control and Prevention to evaluate changes in the burden of invasive disease, defined by isolation of streptococcus pneumoniae from a normally sterile site. Serotyping and susceptibility testing of isolates were performed. We assessed trends using data from seven geographic areas with continuous participation from 1998 through 2001 (population, 16 million). RESULTS: The rate of invasive disease dropped from an average of 24.3 cases per 100,000 persons in 1998 and 1999 to 17.3 per 100,000 in 2001. The largest decline was in children under two years of age. In this group, the rate of disease was 69 percent lower in 2001 than the base-line rate (59.0 cases per 100,000 vs. 188.0 per 100,000, P<0.001); the rate of disease caused by vaccine and vaccine-related serotypes declined by 78 percent (P<0.001) and 50 percent (P<0.001), respectively. Disease rates also fell for adults; as compared with baseline, the rate of disease in 2001 was 32 percent lower for adults 20 to 39 years of age (7.6 cases per 100,000 vs. 11.2 per 100,000, P<0.001), 8 percentlower for those 40 to 64 years of age (19.7 per 100,000 vs. 21.5 per 100,000, P=0.03), and 18 percent lower for those 65 years of age or more (49.5 per 100,000 vs. 60.1 per 100,000, P<0.001). The rate of disease caused by strains that were not susceptible to penicillin was 35 percent lower in 2001 than in 1999 (4.1 cases per 100,000 vs. 6.3 per 100,000, P<0.001). CONCLUSIONS: The use of the pneumococcal conjugate vaccine is preventing disease in young children, for whom the vaccine is indicated, and may be reducing the rate of disease in adults. The vaccine provides an effective new tool for reducing disease caused by drug-resistant strains.

UR - http://www.scopus.com/inward/record.url?scp=0242684416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242684416&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa022823

DO - 10.1056/NEJMoa022823

M3 - Article

C2 - 12724479

AN - SCOPUS:0242684416

VL - 348

SP - 1737

EP - 1746

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 18

ER -